IP Library › Granted Patent US 9,206,235
Granted Patent B2
US 9,206,235 · App. 14/078,043 · Granted Dec 8, 2015

Peptide linkers for polypeptide compositions and methods for using same

Inventors: Paolo Martini (Boston, MA); Michael Concino (Bolton, MA)
Assignee: Shire Human Genetic Therapies, Inc.
C07K14/00A61K38/30A61K38/465A61K38/47A61K47/48338C07K7/08C07K14/65C12N9/2402C12Y302/0105A61K9/0019C07K2319/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,206,235
App. No.
14/078,043
Granted
Dec 8, 2015
Kind
B2
Abstract

Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in order to treat various diseases or disorders (e.g., lysosomal storage disorders).

Claims (22)

1. An isolated polypeptide linker comprising the amino acid sequence of SEQ ID NO: 1, except one or more alanine residues of the amino acid sequence of SEQ ID NO: 1 are substituted with a serine residue.

2. The isolated polypeptide linker of claim 1 , wherein said linker further comprises the amino acid sequence glycine-alanine-proline (GAP) at the C-terminus of said linker.

3. An isolated fusion polypeptide composition comprising the linker of claim 1 , further comprising a first peptide and a second peptide, wherein said linker is disposed between the first peptide and the second peptide.

4. The isolated fusion polypeptide composition of claim 3 , wherein said first peptide comprises the amino acid sequence of SEQ ID NO: 4.

5. The isolated fusion polypeptide composition of claim 3 , wherein said second peptide comprises a receptor binding domain.

6. The isolated fusion polypeptide composition of claim 3 , wherein said second peptide comprises the amino acid sequence of SEQ ID NO: 6.

7. The isolated fusion polypeptide composition of claim 3 , wherein said first peptide comprises the amino acid sequence of SEQ ID NO: 4 and wherein said second peptide comprises the amino acid sequence of SEQ ID NO: 6.

8. A pharmaceutical fusion composition comprising the isolated fusion polypeptide composition of claim 7 and an acceptable carrier.

9. An isolated polypeptide linker comprising the amino acid sequence of SEQ ID NO: 2, except one or more alanine residues of the amino acid sequence of SEQ ID NO: 2 are substituted with a serine residue.

10. An isolated fusion polypeptide composition comprising said linker of claim 9 , further comprising a first peptide and a second peptide; wherein said linker is disposed between the first peptide and the second peptide.

11. The isolated fusion polypeptide composition of claim 10 , wherein said first peptide comprises the amino acid sequence of SEQ ID NO: 4.

12. The isolated fusion polypeptide composition of claim 10 , wherein said second peptide comprises a receptor binding domain.

13. The isolated fusion polypeptide composition of claim 10 , wherein said second peptide comprises the amino acid sequence of SEQ ID NO: 6.

14. The isolated fusion polypeptide composition of claim 10 , wherein said first peptide comprises the amino acid sequence of SEQ ID NO: 4 and wherein said second peptide comprises the amino acid sequence of SEQ ID NO: 6.

15. A pharmaceutical fusion composition comprising the isolated fusion polypeptide composition of claim 14 and an acceptable carrier.

16. An isolated polypeptide fusion composition comprising a first peptide, a second peptide, and a polypeptide linker; wherein said linker comprises the amino acid sequence of SEQ ID NO: 1, except one or more alanine residues of the amino acid sequence of SEQ ID NO: 1 are substituted with a serine residue, and wherein the isolated fusion polypeptide composition comprises one or more sequential repeats of said linker disposed between said first peptide and said second peptide.

17. The isolated fusion polypeptide composition of claim 16 , wherein said linker further comprises the amino acid sequence glycine-alanine-proline (GAP) at the C-terminus of said linker.

18. The fusion polypeptide composition of claim 16 , wherein said first peptide comprises the amino acid sequence of SEQ ID NO: 4.

19. The fusion polypeptide composition of 16, wherein said second peptide comprises the amino acid sequence of SEQ ID NO: 6.

20. The isolated fusion polypeptide of claim 3 , wherein said fusion polypeptide comprises three sequential repeats of said linker disposed between said first peptide and said second peptide.

21. The isolated polypeptide linker of claim 1 , wherein said linker comprises three sequential repeats of said linker.

22. The isolated polypeptide linker of claim 21 , wherein said linker further comprises the amino acid sequence glycine-alanine-proline (GAP) at the C-terminus of said linker.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2013
From: MARTINI, PAOLO; CONCINO, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 031767/0227 →
Continuity (5)
Continuation 13411287 · Mar 2, 2012
Continuation In Part 13168969 · Jun 25, 2011
Continuation In Part PCTUS2011041928 · Jun 25, 2011
Provisional Application 61449225 · Mar 4, 2011
Related Publication 20140187502A1 · Jul 3, 2014